Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Indalo Therapeutics Initiates Phase 1 Trial of Antifibrotic Drug Candidate IDL-2965

americanpharmaceuticalreviewApril 19, 2019

Tag: Indalo Therapeutics , IDL-2965 , Antifibrotic

PharmaSources Customer Service